
Supplementary Table 1 Glucose and hormone responses to the standard meal test

		Total	uACR<30mg/g	uACR≥30mg/g	p-	
					value	
Glucose		8.3±1.5	8.3±1.5	8.6±1.4	0.004	
0min,mmol/L						
Glucose		11.3±2.1	11.3±2.1	11.4±2.2	0.248	
30min,mmol/L						
Glucose		12.6±3.0	12.5±3.0	12.9±2.9	0.079	
120min,mmol	/L					
Glucose		11.1±3.1	11.0±3.1	11.7±2.9	0.026	
180min,mmol/L						
Insulin	0min,	13.3±9.3	12.9±9.6	14.7±8.0	0.082	
$\mu IU/mL$						
Insulin	30min,	21.8±13.3	21.3±13.0	23.8±14.0	0.068	
$\mu IU/mL$						
Insulin	120min,	34.6±18.5	33.6±17.9	38.0±20.2	0.016	
$\mu IU/mL$						
Insulin	180min,	28.9±16.7	28.2±16.5	31.5±17.2	0.027	
μIU/mL						
Glucagon	0min,	75.5±30.4	74.8±29.8	78.1±32.3	0.736	
pg/mL						
Glucagon	30min,	80.2±34.0	79.7±33.0	81.6±36.8	0.631	
pg/mL						
Glucagon	120min,	71.6±34.2	71.4±31.7	73.7±42.2	0.515	
pg/mL						
Glucagon	180min,	66.6±32.8	67.1±31.6	67.1±37.4	0.998	
pg/mL						
GLP-1 0min, pmol		17.4±13.3	17.9±13.4	16.8±13.5	0.276	

GLP-1 30min, pmol	19.0±15.1		19.9±15.6	16.7±13.3		0.007
GLP-1 120min, pmol	17.4±13.9		18.4±13.8	16.0±14.1		0.037
GLP-1 180min, pmol	18.2±15.7		19.0±16.0	17.1±14.5		0.116
AUCglucose,	1347(1180	to	2027(1767 to 2345)	2109(1852	to	0.036
mmol/L×min	1534			2405		
AUCinsulin,	4567(3186	to	4379(3074 to 6176)	4959(3507	to	0.615
μIU/mL×min	6262)			7022)		
AUCglucagon,	12458(9776	to	12458(10004 to	12458(9338	to	0.019
pg/mL×min	15896		15929)	15927)		
AUCGLP-1,	2800(1701	to	2896(1763 to 4725)	2257(1585	to	0.003
pmol×min	4440)			3506)		

Values are presented as means±SD or median (IQR). GLP-1: glucagon-like peptide 1; AUCglucose: area under the glucose curve; AUCinsulin: area under the insulin curve; AUCglucagon: area under the glucagon curve; AUCGLP-1: area under the GLP-1 curve



Excluded

- history of renal disease with a plasma creatinine concentration of 133 μmol/L (1·5 mg/dL) or more;
- cardiac diseases (a history of unstable angina or myocardial infarction within the previous 6 months or New York Heart Association class III or IV congestive heart failure);
- severe gastrointestinal diseases or hepatic diseases, or an aspartate amino transferase or alanine aminotransferase concentration at least twice as high as the upper limit of the normal range;
- chronic hypoxic diseases (emphysema or cor pulmonale);
- haematological diseases;
- endocrine diseases (hypo thyroidism, hyperthyroidism, Cushing's syndrome);
- uncontrolled hypertension (systolic pressure ≥160 mm Hg or diastolic pressure ≥95 mm Hg);
- acute illness;
- a history of intestinal surgery; women with the potential to become pregnant, who were preparing for conception, or who were pregnant or breastfeeding;
- participation in any drug clinical trials during the past 3 months before enrolment;
- mental disorders;
- drug or other substance misuse;
- requirement for insulin therapy;

copyright©the author(s)2022.

Supplementary Figure 1 The study flowchart. T2DM, type 2 diabetes mellitus; GLP-1, glucagon-like peptide 1.